Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses DNLI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DNLI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ryan Watts | $718,000 | $676,706 | $1,151,867 | $2,180,003 | $0 | $0 | $24,939 | $4,751,515 |
| President and Chief Executive Officer | ||||||||
| Alexander Schuth | 552,000 | 360,175 | 1,151,867 | 2,180,003 | 0 | 0 | 14,000 | 4,258,045 |
| Chief Operating and Financial Officer and Secretary | ||||||||
| Carole Ho | 483,000 | 0 | 1,151,867 | 2,180,003 | 0 | 0 | 14,000 | 3,828,870 |
| Chief Medical Officer and Head of Development (until November 14, 2025) | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ryan Watts | $4,751,515 | $6,557,662 | $7,879,267 | −1,806,147 |
| Alexander Schuth | 4,258,045 | 4,022,759 | 4,169,183 | +235,286 |
| Carole Ho | 3,828,870 | 4,022,759 | 4,169,183 | −193,889 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jay Flatley | Director | 2026-06-03 | A | 6,408 | $0 | $0 | Common | Form 4 ↗ |
| David P. Schenkein | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy A. Thornberry | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tim Van Hauwermeiren | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| Jay Flatley | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steve E. Krognes | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| David P. Schenkein | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| Nancy A. Thornberry | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer Cook | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Klein | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| Peter Klein | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steve E. Krognes | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tim Van Hauwermeiren | Director | 2026-06-03 | A | 6,408 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer Cook | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-06-03 | A | 19,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ryan Watts | OPTION | 2025-01-03 | — | — | 162,540 | — | $2,180,003 |
| Ryan Watts | OPTION | 2025-01-03 | — | — | 54,180 | — | 1,151,867 |
| Carole Ho | OPTION | 2025-01-03 | — | — | 162,540 | — | 2,180,003 |
| Alexander Schuth | OPTION | 2025-01-03 | — | — | 54,180 | — | 1,151,867 |
| Alexander Schuth | OPTION | 2025-01-03 | — | — | 162,540 | — | 2,180,003 |
| Carole Ho | OPTION | 2025-01-03 | — | — | — | — | 1,151,867 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ryan Watts | $0 | $0 | $3,331,870 | 0.0% |
| Carole Ho | 0 | 0 | 3,331,870 | 0.0% |
| Alexander Schuth | 0 | 0 | 3,331,870 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ryan Watts | RSU | 54,180 | — | $894,512 |
| Carole Ho | RSU | 54,180 | — | 894,512 |
| Alexander Schuth | RSU | 40,290 | — | 665,188 |
| Carole Ho | RSU | 40,290 | — | 665,188 |
| Alexander Schuth | RSU | 7,750 | — | 127,953 |
| Carole Ho | RSU | 7,750 | — | 127,953 |
| Alexander Schuth | Option | 162,540 | 21.26 | — |
| Carole Ho | Option | 83,938 | 20.33 | — |
| Ryan Watts | RSU | 41,120 | — | 678,891 |
| Carole Ho | RSU | 20,560 | — | 339,446 |
| Alexander Schuth | RSU | 5,625 | — | 92,869 |
| Ryan Watts | RSU | 15,500 | — | 255,905 |
| Ryan Watts | Option | 162,540 | 21.26 | — |
| Alexander Schuth | Option | 1,939 | 47.27 | — |
| Ryan Watts | Option | 66,822 | 27.63 | — |
| Alexander Schuth | RSU | 54,180 | — | 894,512 |
| Alexander Schuth | RSU | 20,560 | — | 339,446 |
| Carole Ho | RSU | 5,625 | — | 92,869 |
| Alexander Schuth | Option | 33,411 | 27.63 | — |
| Alexander Schuth | Option | 83,938 | 20.33 | — |
| Carole Ho | Option | 33,411 | 27.63 | — |
| Carole Ho | Option | 1,939 | 47.27 | — |
| Carole Ho | Option | 162,540 | 21.26 | — |
| Ryan Watts | RSU | 67,140 | — | 1,108,481 |
| Ryan Watts | Option | 3,888 | 47.27 | — |
| Ryan Watts | Option | 139,875 | 20.33 | — |
Our compensation committee believes a well-designed compensation program should align executive interests with the drivers of growth and stockholder returns by supporting the Company s achievement of its primary business goals, and the Company s ability to attract and retain employees whose talents, expertise, leadership, and contributions are expected to sustain growth in long-term stockholder value.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 117,038,745 | 7,088,810 | 717,733 | 93.75% | Passed |
| 2025 | 2025-06-03 | 109,412,774 | 10,796,945 | 681,758 | 90.5% | Passed |
| 2024 | 2024-05-31 | 101,612,037 | 8,587,858 | 43,410 | 92.17% | Passed |
| 2023 | 2023-06-01 | 98,002,580 | 6,571,884 | 50,220 | 93.67% | Passed |
| 2022 | 2022-06-02 | 75,783,360 | 4,516,536 | 649,358 | 93.62% | Passed |
| 2021 | 2021-06-02 | 100,992,741 | 2,290,840 | 703,961 | 97.12% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | 93.75%a |
| 2025 | 2025-06-03 | 90.5%b |
| 2024 | 2024-05-31 | 92.17%c |
a. Approved under the standard stated in the filing — “2, the abstention will have the same effect as a vote AGAINST the proposal.”.
b. Approved under the standard stated in the filing — “2, the abstention will have the same effect as a vote AGAINST the proposal.”.
c. Approved under the standard stated in the filing — “2, the abstention will have the same effect as a vote AGAINST the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 12.8 : 1 |
|---|---|
| CEO total compensation | $4,751,515 |
| Median employee compensation | $370,857 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Julian C. BakerIndependent · Board Chair · Corporate Governance and Nominating · Newly elected | $51,923 | $147,170 | $275,255 | $0 | $0 | $474,348 |
| Tim Van HauwermeirenIndependent · Audit · Newly elected | 8,288 | 158,629 | 301,044 | 0 | 0 | 467,961 |
| Peter KleinIndependent · Audit (Chair) · Compensation | 77,500 | 84,095 | 157,285 | 0 | 0 | 318,880 |
| Jay FlatleyIndependent · Audit · Compensation (Chair) | 75,000 | 84,095 | 157,285 | 0 | 0 | 316,380 |
| David Schenkein, M.DIndependent · Corporate Governance and Nominating | 70,000 | 84,095 | 157,285 | 0 | 0 | 311,380 |
| Nancy A. ThornberryIndependent · Compensation · Corporate Governance and Nominating | 65,000 | 84,095 | 157,285 | 0 | 0 | 306,380 |
| Jennifer CookIndependent · Corporate Governance and Nominating | 60,000 | 84,095 | 157,285 | 0 | 0 | 301,380 |
| Steve E. KrognesIndependent · Audit | 55,769 | 84,095 | 157,285 | 0 | 0 | 297,149 |
| Marc Tessier-Lavigne, Ph.DIndependent · Not standing for re-election · Departed during FY | 40,553 | 84,095 | 157,285 | 0 | 0 | 281,933 |
| Vicki Sato, Ph.DIndependent · Not standing for re-election · Departed during FY | 38,077 | 199,990 | — | 0 | 0 | 238,067 |
| Erik HarrisIndependent · Not standing for re-election · Departed during FY | 25,385 | — | — | 0 | 0 | 25,385 |
| Ryan J. Watts, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x base annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $567,495 |
| Equity awards (grant-date value) | $1,094,454 |
| All other compensation | $0 |
| Total cost of the board | $1,661,949 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Denali Therapeutics Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Denali Therapeutics Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BridgeBio Pharma | 2025 | Neil Kumar | $1,044,000 | $10,606,275 | $1,874,992 | $0 | $14,944,585 |
| 2 | Revolution Medicines | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 3 | Vaxcyte | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 4 | Biohaven | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 5 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 6 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 7 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 8 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 9 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 10 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 11 | Vir Biotechnology | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 12 | CRISPR Therapeutics | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 13 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 14 | Prothena Corporation | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 15 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 16 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 17 | Intellia Therapeutics | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 18 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 19 | Neumora Therapeutics | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 20 | REGENXBIO | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 21 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 22 | Alector Therapeutics | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 23 | Iovance Biotherapeutics | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
| — | Avidity Biosciences | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Agios Pharmaceuticals | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| Alector Therapeutics | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Avidity Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Biohaven | 67% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon (Human Capital Solutions practice, formerly Radford) |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| CRISPR Therapeutics | 122.5% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Intellia Therapeutics | 115% | Options 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine Rewards, LLC |
| Intra-Cellular Therapies | 150% | RSU 75 · PSU 25 | Yes — Total Stockholder Return (TSR) relative to Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Iovance Biotherapeutics | 60% | not disclosed | No | Haigh & Company |
| Neumora Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Prothena Corporation | 100% | not disclosed | not disclosed | Pay Governance |
| REGENXBIO | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| Revolution Medicines | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vaxcyte | 105% | not disclosed | not disclosed | Pay Governance |
| Vir Biotechnology | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Ryan Watts | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Summary Compensation Table For Fiscal”. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 2 | Section 01, Alexander Schuth | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Summary Compensation Table For Fiscal”. As printed: 4,258,045. Filing ↗machine: t25 · r5 · c25 · span 481926–481935 |
| 3 | Section 01, Carole Ho | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Summary Compensation Table For Fiscal”. As printed: 3,828,870. Filing ↗machine: t25 · r11 · c25 · span 495962–495971 |
| 4 | Section 03, Ryan Watts OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r2 · c17 · span 468230–468239 |
| 5 | Section 03, Ryan Watts OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r2 · c13 · span 467541–467550 |
| 6 | Section 03, Carole Ho OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r11 · c17 · span 494761–494770 |
| 7 | Section 03, Alexander Schuth OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r5 · c13 · span 480123–480132 |
| 8 | Section 03, Alexander Schuth OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r5 · c17 · span 480725–480734 |
| 9 | Section 03, Carole Ho OPTION | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t25 · r11 · c13 · span 494159–494168 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “CEO Pay Ratio”. As printed: 12.8 : 1. Filing ↗machine: span 765664–765668 |
| 11 | Section 08, Julian C. Baker | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 474,348. Filing ↗machine: t47 · r3 · c15 · span 956442–956449 |
| 12 | Section 08, Tim Van Hauwermeiren | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 467,961. Filing ↗machine: t47 · r10 · c15 · span 974753–974760 |
| 13 | Section 08, Peter Klein | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 318,880. Filing ↗machine: t47 · r6 · c15 · span 964277–964284 |
| 14 | Section 08, Jay Flatley | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 316,380. Filing ↗machine: t47 · r5 · c15 · span 961666–961673 |
| 15 | Section 08, David Schenkein, M.D | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 311,380. Filing ↗machine: t47 · r8 · c15 · span 969514–969521 |
| 16 | Section 08, Nancy A. Thornberry | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 306,380. Filing ↗machine: t47 · r9 · c15 · span 972133–972140 |
| 17 | Section 08, Jennifer Cook | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 301,380. Filing ↗machine: t47 · r4 · c15 · span 959055–959062 |
| 18 | Section 08, Steve E. Krognes | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 297,149. Filing ↗machine: t47 · r7 · c15 · span 966893–966900 |
| 19 | Section 08, Marc Tessier-Lavigne, Ph.D | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 281,933. Filing ↗machine: t47 · r14 · c15 · span 983569–983576 |
| 20 | Section 08, Vicki Sato, Ph.D | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 238,067. Filing ↗machine: t47 · r12 · c15 · span 978331–978338 |
| 21 | Section 08, Erik Harris | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 25,385. Filing ↗machine: t47 · r13 · c3 · span 979171–979177 |
| 22 | Section 08, Ryan J. Watts, Ph.D | DEF 14A | 2026-04-21 | 0001714899-26-000054 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Jay Flatley 2026-06-03 | Form 4 | 2026-06-05 | 0001189130-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, David P. Schenkein 2026-06-03 | Form 4 | 2026-06-05 | 0001578200-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Nancy A. Thornberry 2026-06-03 | Form 4 | 2026-06-05 | 0001797826-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Tim Van Hauwermeiren 2026-06-03 | Form 4 | 2026-06-05 | 0001816206-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, BAKER BROS. ADVISORS LP 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259680 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Jay Flatley 2026-06-03 | Form 4 | 2026-06-05 | 0001189130-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Steve E. Krognes 2026-06-03 | Form 4 | 2026-06-05 | 0001666236-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, David P. Schenkein 2026-06-03 | Form 4 | 2026-06-05 | 0001578200-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Nancy A. Thornberry 2026-06-03 | Form 4 | 2026-06-05 | 0001797826-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jennifer Cook 2026-06-03 | Form 4 | 2026-06-05 | 0001754371-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, BAKER BROS. ADVISORS LP 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259680 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, BAKER BROS. ADVISORS LP 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259680 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Peter Klein 2026-06-03 | Form 4 | 2026-06-05 | 0001478007-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Peter Klein 2026-06-03 | Form 4 | 2026-06-05 | 0001478007-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Steve E. Krognes 2026-06-03 | Form 4 | 2026-06-05 | 0001666236-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Tim Van Hauwermeiren 2026-06-03 | Form 4 | 2026-06-05 | 0001816206-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Jennifer Cook 2026-06-03 | Form 4 | 2026-06-05 | 0001754371-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, BAKER BROS. ADVISORS LP 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259680 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001714899-26-000074 | Item 5.07 · say-on-pay result. As reported: 93.75% (votes for as printed: 117,038,745). Filing ↗ |
| 42 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0001714899-25-000128 | Item 5.07 · say-on-pay result. As reported: 90.5% (votes for as printed: 109,412,774). Filing ↗ |
| 43 | Section 06, 2024 vote | Form 8-K | 2024-05-31 | 0001714899-24-000125 | Item 5.07 · say-on-pay result. As reported: 92.17% (votes for as printed: 101,612,037). Filing ↗ |
| 44 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 45 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 46 | Section 09b board cost (computed) | Computed | — | computed | Cash 567,495 + equity 1,094,454 + all other 0 = 1,661,949, summed across the director compensation table rows.machine: formula: Σ = 1,661,949 |
| 47 | BridgeBio Pharma, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 48 | Revolution Medicines, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines's own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 49 | Vaxcyte, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 50 | Biohaven, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001935979-26-000028 | CEO total compensation as printed in Biohaven's own proxy. As printed: 13,500,438. Filing ↗machine: t25 · r3 · c7 · span 423429–423439 |
| 51 | Blueprint Medicines, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: t150 · r5 · c14 · span 1101152–1101162 |
| 52 | Cytokinetics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001140361-26-015364 | CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103 |
| 53 | Ultragenyx Pharmaceutical, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 54 | Axsome Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 55 | Intra-Cellular Therapies, Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 56 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 57 | Vir Biotechnology, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025379 | CEO total compensation as printed in Vir Biotechnology's own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922 |
| 58 | CRISPR Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics's own proxy. As printed: 7,678,477. Filing ↗machine: t21 · r2 · c26 · span 821649–821658 |
| 59 | Sage Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-058060 | CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793 |
| 60 | Prothena Corporation, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001559053-26-000012 | CEO total compensation as printed in Prothena Corporation's own proxy. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025 |
| 61 | Beam Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 62 | Agios Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 63 | Intellia Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197283 | CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299 |
| 64 | Denali Therapeutics Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 65 | Neumora Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161489 | CEO total compensation as printed in Neumora Therapeutics's own proxy. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819 |
| 66 | REGENXBIO, Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-155058 | CEO total compensation as printed in REGENXBIO's own proxy. As printed: 4,200,712. Filing ↗machine: r2 · c16 · span 436444–436453 |
| 67 | Dyne Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 68 | Alector Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector Therapeutics's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 69 | Iovance Biotherapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050458 | CEO total compensation as printed in Iovance Biotherapeutics's own proxy. As printed: 1,888,175. Filing ↗machine: t133 · r6 · c16 · span 797910–797919 |
| 70 | Section 10a, BridgeBio Pharma reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 71 | Section 10a, Intellia Therapeutics reciprocity | DEF 14A | — | 0001193125-26-197283 | Intellia Therapeutics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 72 | Section 10a, Ultragenyx Pharmaceutical reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 73 | Section 10a, Beam Therapeutics reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 74 | Section 10a, Blueprint Medicines reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 75 | Section 10a, Dyne Therapeutics reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, Axsome Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 77 | Section 10a, Prothena Corporation reciprocity | DEF 14A | — | 0001559053-26-000012 | Prothena Corporation names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 78 | Section 10a, Intra-Cellular Therapies reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 79 | Section 10a, Sage Therapeutics reciprocity | DEF 14A | — | 0000950170-25-058060 | Sage Therapeutics's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 80 | Section 10a, Vaxcyte reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 81 | Section 10a, Cytokinetics reciprocity | DEF 14A | — | 0001140361-26-015364 | Cytokinetics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Iovance Biotherapeutics reciprocity | DEF 14A | — | 0001104659-26-050458 | Iovance Biotherapeutics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, Biohaven reciprocity | DEF 14A | — | 0001935979-26-000028 | Biohaven names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 84 | Section 10a, Agios Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 85 | Section 10a, Revolution Medicines reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Alector Therapeutics reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector Therapeutics's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 87 | Section 10a, Vir Biotechnology reciprocity | DEF 14A | — | 0001628280-26-025379 | Vir Biotechnology's most recent proxy was read; its disclosed peer group does not include Denali Therapeutics Inc.. Filing ↗ |
| 88 | Section 10a, CRISPR Therapeutics reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics names Denali Therapeutics Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |